Samsung has built a family of AI models trained to interpret raw biosignal data captured by its wearables, rather than working only from the pre-processed metrics that show up on a Galaxy Watch screen, according to AI News.

That distinction matters more than it sounds. Every consumer wearable already turns sensor data into numbers a user can read — heart rate, blood oxygen, sleep stages, stress scores. What's new here is training models directly on the underlying signal stream itself, before it gets compressed into those single-number summaries.

The move puts Samsung in a race that has quietly been building across the wearable industry: turning biosignals — the raw electrical and optical waveforms produced by the heart, lungs and skin — into a modeling substrate on par with text and images, rather than treating them as inputs to fixed, hand-tuned algorithms.

From dashboards to raw waveforms

Wearables like the Galaxy Watch already collect a lot more than they display. The BioActive sensor stack behind Samsung's watches captures photoplethysmography (PPG) signals for heart rate and blood oxygen, single-lead ECG waveforms, and bioelectrical impedance readings for body composition — all sampled continuously, second by second.

Historically, that raw data gets fed through firmware-level signal-processing pipelines that are purpose-built for one job each: one algorithm flags atrial fibrillation, another estimates sleep stage, another smooths out motion artifacts during a workout. Each pipeline is hand-tuned, narrow in scope, and has to be rebuilt or retrained whenever Samsung wants to add a new capability.

Training a model on the raw waveform instead — the approach AI News describes Samsung pursuing — lets one shared representation of the signal feed multiple downstream tasks. That's the same logic that drove foundation models in language and vision: learn a general representation once, then fine-tune or prompt it for many specific jobs, instead of building a bespoke pipeline for each one.

Where biosignal models get hard

Building AI models around physiological signals is a different engineering problem than text or images, and it runs into constraints that don't show up in a typical LLM project:

• Labeled data is scarce for anything beyond the most common conditions — arrhythmias, sleep apnea events and stress spikes are rare relative to normal, healthy signal, which skews training data.
• Motion artifacts, skin tone, strap tightness and wrist placement all distort PPG and ECG readings, so a model has to generalize across noisy, inconsistent real-world capture conditions rather than clean lab data.
• Physiological baselines vary enormously between individuals, so a model that performs well on average can still misfire for users whose resting signal looks unusual.
• Inference has to run continuously on a battery-constrained device, or be streamed to the cloud, which raises both latency and privacy tradeoffs.
• Any output that reads as a diagnosis, rather than a wellness metric, invites regulatory scrutiny, which shapes what a company is willing to claim publicly about a model's accuracy.

What it means for AI builders

For teams working outside of Samsung, the immediate takeaway isn't a new API to integrate — nothing in the reporting suggests these models are being opened up to third-party developers. The more useful signal is directional: time-series foundation models trained on continuous sensor streams are becoming a distinct product category, not just a research curiosity.

Anyone building on top of wearable or IoT sensor data should expect two things to matter more over the next year: model compression techniques that make on-device inference viable on battery-constrained hardware, and evaluation methods that account for individual baseline variation rather than population averages. Both are underdeveloped relative to how mature they are in text and vision.

AiiN's takeaway

Samsung's project is part of a broader pattern of large tech companies pushing foundation-model techniques into domains further from language — physiological signals, in this case — where the payoff is a single adaptable model instead of a pile of narrow, hand-built ones. In our estimation, turning that into products with clinical-grade credibility will likely take considerably longer than the modeling work itself, given the data, personalization and regulatory hurdles involved. For now, the more concrete story is architectural: a major device maker is treating raw biosignal streams, not dashboard metrics, as the thing worth training on.